隐匿性乙型肝炎病毒感染状态与淋巴瘤抗 CD19 CAR-T 细胞治疗疗效受损无关且呈现独特的免疫毒性特征：CART-SIE 研究结果

Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct i

低强度 I 型干扰素信号促进 CAR-T 细胞治疗疗效

Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy.

自体 CD5-KO 抗 CD5 CAR-T 细胞在复发/难治性 CD5⁺ 血液系统恶性肿瘤中的疗效与安全性

Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed/refractory CD5(+) hematological malignancies.

CXCR4 修饰通过改善 B 细胞恶性肿瘤的肿瘤追踪与骨髓归巢增强 CAR-T 疗效

CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies.

抗原结合域理性重设计提高 CD22-CAR 的体内疗效

Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR.

CAR-T 细胞治疗前基于苯达莫司汀的淋巴细胞清除：一项系统综述

Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review.

表达白细胞介素 10 的超低剂量 CAR-T 细胞治疗复发/难治性弥漫大 B 细胞淋巴瘤：非随机临床试验

Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinic

这项非随机临床试验的结果表明，超低剂量 META 10-19 在 R/R DLBCL 患者中显示出令人鼓舞的抗肿瘤活性和可控的安全性。有必要在更大队列中进一步研究。

CD19/CD22 双价 CAR-T 细胞治疗儿童、青少年与年轻成人 B-ALL：1 期试验最终结果

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

去甲基化预处理的串联 CD19/CD20 CAR-T 细胞治疗复发/难治性 B 细胞淋巴瘤：一项 I/II 期试验

Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.

CAR-T 细胞治疗作为首次完全缓解 B-ALL 老年患者的确定性巩固治疗

CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission.